Meeting preview
ASH 2026: Preparing for the annual meeting in New Orleans
The 68th ASH Annual Meeting and Exposition, taking place December 12–15, 2026, in New Orleans and online, brings together new research spanning malignant and classical hematology. Conference Insider will provide an independent editorial lens on research relevant to lymphoma and DLBCL, examining the questions behind emerging data, how new findings fit within the evolving treatment landscape, and the potential implications for patient care.
From biologic insight to treatment strategy
Advances in DLBCL increasingly connect disease biology, molecular characteristics, treatment response, and therapeutic decision-making. As new basic, translational, and clinical research emerges around ASH 2026, Conference Insider will look beyond individual findings to consider how the evidence fits within the existing treatment landscape, which patient populations may be most affected, and what new approaches could mean for clinical practice.
Individualizing decisions across the continuum
Disease characteristics, molecular risk, prior therapy, treatment response, patient fitness, and access to care can all influence DLBCL treatment decisions. Our coverage will examine questions surrounding treatment selection and sequencing, biomarkers and response assessment, cellular and immune-based therapies, and evolving strategies for patients with relapsed or refractory disease.
A practical lens for the clinical team
Translating advances in lymphoma research into practice often requires coordination across the care team. Hematologists, oncologists, advanced practice providers, pharmacists, pathologists, nurses, and other specialists each play a role in treatment planning and ongoing management. Conference Insider will highlight where emerging evidence may influence clinical decision-making, where uncertainty remains, and which questions warrant continued attention following ASH 2026.
What Conference Insider will cover
Our ASH 2026 coverage will provide concise, clinically relevant reporting for healthcare professionals seeking context beyond the headlines. Readers can expect selected news updates, focused articles, and expert-oriented summaries exploring DLBCL and the broader lymphoma landscape, with particular attention to emerging therapies, treatment sequencing, biomarkers, molecular profiling, response assessment, cellular therapy, and other developments that may help shape future patient care.
Source: American Society of Hematology — 2026 annual meeting.